SingStrong: Strong Lungs Through Song - Long COVID-19 Study (ss)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04810065|
Recruitment Status : Recruiting
First Posted : March 22, 2021
Last Update Posted : April 14, 2021
|Condition or disease||Intervention/treatment||Phase|
|Long Covid||Other: SingStrong: Strong lungs through Song||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||35 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||SingStrong: Strong Lungs Through Song|
|Actual Study Start Date :||March 29, 2021|
|Estimated Primary Completion Date :||July 2021|
|Estimated Study Completion Date :||September 30, 2021|
SingStrong for Pulmonary Fibrosis
This arm of the project explores Singing as an intervention for people suffering from Pulmonary Fibrosis specifically.
It is a 10 week programme. All other aspects of the intervention are the same in terms of delivery and length of classes.
Different outcome measures, namely the St Georges Respiratory Questionnaire is used in this trial. This is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.
Other: SingStrong: Strong lungs through Song
Participants who have been clinically diagnosed with Covid-19 and who continue to suffer residual adverse effects on the lung health will be invited to participate in the study.
The intervention will involve biweekly hour-long breathing and singing classes that are designed to correct dis-ordered breathing, and retrain the principal muscles of respiration.
Pre and post evaluation of participant bio-psychosocial health and wellness will be conducted. Triangulation of data using focus groups and individual interviews will be conducted after conclusion of the intervention,
- Covid-19 Yorkshire Rehab Screen (C19YRS) [ Time Frame: 12 weeks ]The C19YRS was developed as a screening tool to monitor long-term symptoms due to Covid-19. The screening tool covers 19 items which combines yes/no answers and an 11 point ordinal scale (0-10) where a higher score denotes increased symptom severity.
- DePaul Symptom Questionnaire - Short Form DSQ - SF [ Time Frame: 12 weeks ]The DPSQ -SF assesses key symptoms of ME/Chronic Fatigue Syndrome such as fatigue, post-exertional malaise, sleep, pain, neurological/cognitive impairments and autonomic, neuroendocrine and immune symptoms. At each item, participants have to rate the frequency and severity of the symptom on a scale from 0 to 4. A higher score denotes increased symptom severity.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04810065
|Contact: Roisin Cahalan, PhD||+35361 firstname.lastname@example.org|
|University of Limerick||Recruiting|
|Contact: Roisin Cahalan, PhD|
|Principal Investigator:||Roisin Cahalan, PhD||University of Limerick|